United Therapeutics Corporation (FRA:UTH)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.04B +20.4% |
| Revenue (ttm) | 2.76B +2.5% |
| Net Income | 1.15B +5.5% |
| EPS | 24.46 +9.0% |
| Shares Out | n/a |
| PE Ratio | 18.33 |
| Forward PE | 17.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 472.10 |
| Previous Close | 471.30 |
| Day's Range | 472.10 - 481.50 |
| 52-Week Range | 356.90 - 522.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About United Therapeutics
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USD Financial StatementsNews
United Therapeutics price target raised to $708 from $677 at RBC Capital
RBC Capital raised the firm’s price target on United Therapeutics (UTHR) to $708 from $677 and keeps an Outperform rating on the shares as part of a broader research note…
United Therapeutics price target raised to $566 from $515 at Morgan Stanley
Morgan Stanley raised the firm’s price target on United Therapeutics (UTHR) to $566 from $515 and keeps an Equal Weight rating on the shares. The firm adjusted its models for…
Liquidia downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Liquidia to Outperform from Strong Buy with a price target of $53, down from $106. Liquidia’s (LQDA) Delaware court loss on United Therapeutics’ (UTHR) ‘327 patent removes…
United Therapeutics’ path to $1,000 ‘just got easier,’ says Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders tells investors in a research note that United Therapeutics’ (UTHR) path to $1,000 “just got easier” following the patent infringement ruling over Liqu...
United Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded United Therapeutics (UTHR) to Buy from Neutral with a $728 price target. The company’s legal win against Liquidia (LQDA) (LQDQ) “clears a path” to resumed growth through 2027,…
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court ...
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
Patent ruling ‘a meaningful positive’ for United Therapeutics, says RBC Capital
RBC Capital notes that the U.S. District Court for the District of Delawareissued its ruling finding that Liquidia (LQDA) has infringed Claims 1 and 14 of United Therapeutics’ (UTHR) U.S.
Liquidia says court ruled two of six ‘327 patent claims infringed by company
Liquidia (LQDA) issued an update regarding the litigation filed by United Therapeutics (UTHR) in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent…
Judge upholds claims 1, 14 of United Therapeutics’ ‘327 patent
A judge has upheld claims 1 and 4 of United Therapeutics’ (UTHR) ‘327 patent, ruling that Liquidia (LQDA) has infringed on the patent. A final judgment is due within one…
United Therapeutics up 13% to $543.85 following Liquidia patent ruling
12:11 EDT United Therapeutics (UTHR) up 13% to $543.85 following Liquidia (LQDA) patent ruling
United Therapeutics rises 13.2%
United Therapeutics (UTHR) is up 13.2%, or $63.59 to $545.06.
United Therapeutics up 10% as Liquidia halted
Shares of Liquidia Technologies (LQDA) were down sharply before the stock was halted, pending news. Shares of United Therapeutics (UTHR), which has been in a patent fight with Liquidia, are…
United Therapeutics initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics (UTHR) with a Sell rating and $321 price target which represents 34% downside. The shares trade at a premium its…
United Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Fourteen new therapies are being launched for pulmonary and fibrotic diseases, with a focus on disruptive innovation, robust financial stewardship, and a transformative organ manufacturing program targeting commercial launch by 2030. AI-driven drug development and a high-efficiency culture underpin rapid growth and industry leadership.
United Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A major strategic shift is underway, expanding from orphan pulmonary hypertension to large pulmonary fibrosis markets, with strong clinical data supporting new launches and ambitious revenue targets. Multiple product formulations and sales force expansions are planned, while regulatory confidence remains high for upcoming approvals.
United Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major clinical and commercial transformation is underway, with best-in-class pulmonary fibrosis data, a rapidly expanding addressable market, and 14 product launches planned through 2029. Launch readiness, polypharmacy strategies, and a $500 million stock buyback highlight strong momentum and confidence in reaching $50–$100 billion in revenue by the early 2030s.
United Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Fourteen new products are set for rapid launch, targeting $50–100 billion in annual pharma revenue and addressing a million-patient market. Key innovations include once-daily and coughless inhalers, with strong IP protection and major investments in manufacturing and xenotransplantation.
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the rema...
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the suppleme...
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fir...
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four p...
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug...
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (trepr...
United Therapeutics Earnings Call Transcript: Q2 2026
Exceptional clinical results and major regulatory filings set the stage for multi-billion dollar opportunities in PAH and IPF. Q2 revenue was flat sequentially at $783 million, with competitive pressures on TYVASO but strong underlying patient metrics and expanded sales force supporting a positive outlook for the second half of 2026.